
Sedana Medical Q2 - The US story comes closer

Redeye notes a weak Q2 for Sedana Medical, with lower sales and higher costs than we expected. Still, other direct markets (excl., Germany) developed well and are an important metric to better understand its US prospects, which will be a main focus area going forward as the clinical trials have been fully recruited and are now awaiting data to be presented.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Sedana Medical Q2 - The US story comes closer](#)